Eliminating OVD need via FLACS

Article

Phacoemulsification and intraocular lens implantation can be performed without an ophthalmic viscosurgical device (OVD) by using a femtosecond laser-assisted procedure (FLACS), according to researchers from the Institute for Vision Science, Ruhr University Eye Clinic, Bochum, Germany.

Phacoemulsification and intraocular lens implantation can be performed without an ophthalmic viscosurgical device (OVD) by using a femtosecond laser-assisted procedure (FLACS), according to researchers from the Institute for Vision Science, Ruhr University Eye Clinic, Bochum, Germany.

According to the researchers, performing FLACS without OVD poses no additional risk to the corneal endothelium compared with patients whose surgery was performed with standard phacoemulsification using OVD.

Reporting in the Journal of Refractive Surgery, the researchers conducted a prospective, randomized, single-centre trial of 74 eyes in 37 patients diagnosed as having significant cataracts in both eyes.

 In all of the patients, one eye was randomized to receive standard phacoemulsification with OVD. The other eye was treated with a femtosecond laser, and the subsequent manual part of the procedure was performed without using OVD. The patients were followed for 6 months.

The researchers found that among all the eyes, there were no significant differences in:

• major complications (none in either group)

• overall surgery time (non-OVD: 375 ± 81 seconds; OVD: 362 ± 43 seconds)

• the quantity of fluid passing through the eyes (non-OVD: 187 ± 35 mL; OVD: 186 ± 27 mL)

• endothelial cell loss after 6 months (non-OVD: −2.4%; OVD: −2.7%)

 

• central corneal thickness at 1 week postoperatively (non-OVD: 575 ± 45 µm; OVD: 573 ± 46 µm;)

• corrected distance visual acuity (logMAR non-OVD: 0.024; OVD: 0.038).

The researchers added that at 1 day post-surgery, 1 patient in the non-OVD group experienced intraocular pressure >25 mmHg, compared to 3 patients in the OVD group.

 

To read the abstract of the study, click here

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.